Cargando…

Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis

Polyunsaturated fatty acids (PUFAs) including epoxide-modified ω-3 and ω-6 fatty acids are made via oxidation to create highly polarized carbon-oxygen bonds crucial to their function as signaling molecules. A critical PUFA, arachidonic acid (ARA), is metabolized to a diverse set of lipids signaling...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Ryan D., Liao, Jie, Tong, Xin, Xu, Dandan, Sun, Leyu, Li, Haonan, Yang, Guang-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603234/
https://www.ncbi.nlm.nih.gov/pubmed/31293429
http://dx.doi.org/10.3389/fphar.2019.00731
_version_ 1783431479324311552
author Jones, Ryan D.
Liao, Jie
Tong, Xin
Xu, Dandan
Sun, Leyu
Li, Haonan
Yang, Guang-Yu
author_facet Jones, Ryan D.
Liao, Jie
Tong, Xin
Xu, Dandan
Sun, Leyu
Li, Haonan
Yang, Guang-Yu
author_sort Jones, Ryan D.
collection PubMed
description Polyunsaturated fatty acids (PUFAs) including epoxide-modified ω-3 and ω-6 fatty acids are made via oxidation to create highly polarized carbon-oxygen bonds crucial to their function as signaling molecules. A critical PUFA, arachidonic acid (ARA), is metabolized to a diverse set of lipids signaling molecules through cyclooxygenase (COX), lipoxygenase (LOX), cytochrome P450 epoxygenase, or cytochrome P450 hydroxylase; however, the majority of ARA is metabolized into anti-inflammatory epoxides via cytochrome P450 enzymes. These short-lived epoxide lipids are rapidly metabolized or inactivated by the soluble epoxide hydrolase (sEH) into diol-containing products. sEH inhibition or knockout has been a practical approach to study the biology of the epoxide lipids, and has been shown to effectively treat inflammatory conditions in the preclinical models including gastrointestinal ulcers and colitis by shifting oxylipins to epoxide profiles, inhibiting inflammatory cell infiltration and activation, and enhancing epithelial cell defense via increased mucin production, thus providing further evidence for the role of sEH as a pro-inflammatory protein. Non-steroidal anti-inflammatory drugs (NSAIDs) with COX-inhibitor activity are among the most commonly used analgesics and have demonstrated applications in the management of cardiovascular disease and intriguingly cancer. Major side effects of NSAIDs however are gastrointestinal ulcers which frequently precludes their long-term application. In this review, we hope to bridge the gap between NSAID toxicity and sEH-mediated metabolic pathways to focus on the role of epoxy fatty acid metabolic pathway of PUFAs in NSAIDS-ulcer formation and healing as well as inflammation-related carcinogenesis. Specifically we address the potential application of sEH inhibition to enhance ulcer healing at the site of inflammation via their activity on altered lipid signaling, mitochondrial function, and diminished reactive oxygen species, and further discuss the significance of dual COX and sEH inhibitor in anti-inflammation and carcinogenesis.
format Online
Article
Text
id pubmed-6603234
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66032342019-07-10 Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis Jones, Ryan D. Liao, Jie Tong, Xin Xu, Dandan Sun, Leyu Li, Haonan Yang, Guang-Yu Front Pharmacol Pharmacology Polyunsaturated fatty acids (PUFAs) including epoxide-modified ω-3 and ω-6 fatty acids are made via oxidation to create highly polarized carbon-oxygen bonds crucial to their function as signaling molecules. A critical PUFA, arachidonic acid (ARA), is metabolized to a diverse set of lipids signaling molecules through cyclooxygenase (COX), lipoxygenase (LOX), cytochrome P450 epoxygenase, or cytochrome P450 hydroxylase; however, the majority of ARA is metabolized into anti-inflammatory epoxides via cytochrome P450 enzymes. These short-lived epoxide lipids are rapidly metabolized or inactivated by the soluble epoxide hydrolase (sEH) into diol-containing products. sEH inhibition or knockout has been a practical approach to study the biology of the epoxide lipids, and has been shown to effectively treat inflammatory conditions in the preclinical models including gastrointestinal ulcers and colitis by shifting oxylipins to epoxide profiles, inhibiting inflammatory cell infiltration and activation, and enhancing epithelial cell defense via increased mucin production, thus providing further evidence for the role of sEH as a pro-inflammatory protein. Non-steroidal anti-inflammatory drugs (NSAIDs) with COX-inhibitor activity are among the most commonly used analgesics and have demonstrated applications in the management of cardiovascular disease and intriguingly cancer. Major side effects of NSAIDs however are gastrointestinal ulcers which frequently precludes their long-term application. In this review, we hope to bridge the gap between NSAID toxicity and sEH-mediated metabolic pathways to focus on the role of epoxy fatty acid metabolic pathway of PUFAs in NSAIDS-ulcer formation and healing as well as inflammation-related carcinogenesis. Specifically we address the potential application of sEH inhibition to enhance ulcer healing at the site of inflammation via their activity on altered lipid signaling, mitochondrial function, and diminished reactive oxygen species, and further discuss the significance of dual COX and sEH inhibitor in anti-inflammation and carcinogenesis. Frontiers Media S.A. 2019-06-25 /pmc/articles/PMC6603234/ /pubmed/31293429 http://dx.doi.org/10.3389/fphar.2019.00731 Text en Copyright © 2019 Jones, Liao, Tong, Xu, Sun, Li and Yang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Jones, Ryan D.
Liao, Jie
Tong, Xin
Xu, Dandan
Sun, Leyu
Li, Haonan
Yang, Guang-Yu
Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis
title Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis
title_full Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis
title_fullStr Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis
title_full_unstemmed Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis
title_short Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis
title_sort epoxy-oxylipins and soluble epoxide hydrolase metabolic pathway as targets for nsaid-induced gastroenteropathy and inflammation-associated carcinogenesis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603234/
https://www.ncbi.nlm.nih.gov/pubmed/31293429
http://dx.doi.org/10.3389/fphar.2019.00731
work_keys_str_mv AT jonesryand epoxyoxylipinsandsolubleepoxidehydrolasemetabolicpathwayastargetsfornsaidinducedgastroenteropathyandinflammationassociatedcarcinogenesis
AT liaojie epoxyoxylipinsandsolubleepoxidehydrolasemetabolicpathwayastargetsfornsaidinducedgastroenteropathyandinflammationassociatedcarcinogenesis
AT tongxin epoxyoxylipinsandsolubleepoxidehydrolasemetabolicpathwayastargetsfornsaidinducedgastroenteropathyandinflammationassociatedcarcinogenesis
AT xudandan epoxyoxylipinsandsolubleepoxidehydrolasemetabolicpathwayastargetsfornsaidinducedgastroenteropathyandinflammationassociatedcarcinogenesis
AT sunleyu epoxyoxylipinsandsolubleepoxidehydrolasemetabolicpathwayastargetsfornsaidinducedgastroenteropathyandinflammationassociatedcarcinogenesis
AT lihaonan epoxyoxylipinsandsolubleepoxidehydrolasemetabolicpathwayastargetsfornsaidinducedgastroenteropathyandinflammationassociatedcarcinogenesis
AT yangguangyu epoxyoxylipinsandsolubleepoxidehydrolasemetabolicpathwayastargetsfornsaidinducedgastroenteropathyandinflammationassociatedcarcinogenesis